NCT00589706View on ClinicalTrials.gov

A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 31, 1985

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Gliomas
Interventions
DRUG

MAb-425

MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.

Trial Locations (1)

19102

Hahneman Hospital, Philadelphia

All Listed Sponsors
lead

Drexel University College of Medicine

OTHER

NCT00589706 - A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas | Biotech Hunter | Biotech Hunter